Pulmatrix is a pharmaceutical company specializing in the development of therapies that prevent and control respiratory and infectious diseases. Targeted diseases include influenza, ventilator-acquired pneumonia, respiratory syncytial virus and rhinovirus, as well as COPD, asthma and cystic fibrosis. Among its founding members are professors from Harvard and MIT.